Latest Biotechnology Sector News

Genetic Technologies Limited remains under voluntary administration with minimal cash outflows and $0.276 million in cash as it navigates its Deed of Company Arrangement.

Chimeric Therapeutics Limited has announced a significant 100-to-1 security consolidation affecting shares, options, and performance rights, pending shareholder approval and set for implementation in April 2026.

Argenica Therapeutics has secured a nearly $4 million R&D tax incentive rebate for FY25, strengthening its cash position as it prepares for a pivotal Phase 2b trial of its neuroprotective peptide ARG-007.

Nexalis Therapeutics reported a widening loss of $1.83 million for 2025, reflecting increased investment in product development and marketing. Despite the loss, the company boosted its cash reserves through equity raises and borrowings.

Biome Australia Limited has reported a robust half-year performance, with revenues climbing nearly 40% and net profit more than doubling, driven by strong product momentum and strategic investments.

Patrys Limited has appointed Dr Samantha South as its new CEO, aiming to leverage her biotech expertise to fast-track clinical development and commercialisation of its therapeutic antibody pipeline.

CSL Limited has announced an ordinary dividend of USD 1.30 per share for the six months ending December 2025, payable in April 2026 with multi-currency options for shareholders.

CSL Limited reported a sharp 80% drop in net profit for the half year ended December 2025, driven by significant restructuring and impairment charges, yet maintained its growth guidance and dividend payout.

Hexima Limited reports a stable cash position of $1.4 million for the December quarter while exploring strategic options including a potential capital return to shareholders.

Critica Limited has addressed a recent spike in its share price and trading volume, attributing the movement to positive research coverage while confirming no undisclosed information is driving the activity.

Next Science Limited’s shares have been suspended from ASX trading due to insufficient ongoing operations following the disposal of its main business. The suspension raises questions about the company’s future direction and compliance with listing rules.

Arovella Therapeutics has taken a significant step forward by submitting an IND application to the U.S. FDA for its lead CAR-iNKT cell therapy, ALA-101, targeting blood cancers. This milestone paves the way for a first-in-human Phase 1 trial in both Australia and the U.S.